Project Details
Description
A phase 2/3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to Severely Active Ulcerative Colitis
Status | Finished |
---|---|
Effective start/end date | 12/4/07 → 12/31/14 |
Funding
- JANSSEN BIOTECH, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.